TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02433093

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive 22 days of once-daily oral matching placebo capsules.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive 22 days of once-daily oral matching placebo capsules.
Study: NCT03101592

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Three-month ART dispensing
Description: Patients enrolled in the three-month ART dispensing arm will receive a 90-day supply of ART from their provider for the duration of the study.
Study: NCT02750813

Intervention type: DEVICE
Group type: OTHER
Intervention: Senofilcon A contact lenses

Intervention type: DEVICE
Group type: OTHER
Intervention: Senofilcon A contact lenses
Study: NCT04141345

Intervention type: DIAGNOSTIC_TEST
Intervention: cardiopulmonary exercise test
Description: Patients performed an upright graded bicycle exercise using a personalized protocol or performed a motorized treadmill exercise using a modified Bruce protocol. Peak VO2 and peak respiratory exchange ratio (RER) were defined as the highest 30-second average value obtained during exercise. The anaerobic threshold (AT) was determined by V-slope method. The VE(minute ventilation)/VCO2 (carbon dioxide production) at AT was calculated as the average VE/VCO2 for 1 minute during AT and immediately after AT. If AT could not be determined, the lowest VE/VCO2 was determined by averaging the three lowest consecutive 0.5-minute data points.

Intervention type: DIAGNOSTIC_TEST
Intervention: cardiopulmonary exercise test
Description: Patients performed an upright graded bicycle exercise using a personalized protocol or performed a motorized treadmill exercise using a modified Bruce protocol. Peak VO2 and peak respiratory exchange ratio (RER) were defined as the highest 30-second average value obtained during exercise. The anaerobic threshold (AT) was determined by V-slope method. The VE(minute ventilation)/VCO2 (carbon dioxide production) at AT was calculated as the average VE/VCO2 for 1 minute during AT and immediately after AT. If AT could not be determined, the lowest VE/VCO2 was determined by averaging the three lowest consecutive 0.5-minute data points.
Study: NCT02884791

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: oral carbohydrate challenge
Description: Participants will fast for 8 hours and then drink a beverage containing fructose.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: oral carbohydrate challenge
Description: Participants will fast for 8 hours and then drink a beverage containing fructose.
Study: NCT02461914

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEX168
Description: 200µg,injected subcutaneously,once a week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: 5mg,oral,two times.
Study: NCT02889510

Intervention type: DRUG
Group type: OTHER
Intervention: liraglutide
Description: 7-week subcutaneous liraglutide once daily
Study: NCT03101592

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Six-month ART dispensing
Description: Patients enrolled in the six-month ART dispensing arm will receive a 180-day supply of ART from their provider for the duration of the study.
Study: NCT04479098

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance exercise training
Description: The exercise training program will last 12 weeks, with a frequency of three sessions per week, held on Mondays, Wednesdays, and Fridays. Each session will last approximately 50 minutes. Whenever the maximum number of pre-established repetitions is successfully performed, the intensity will be increased by 5 to 10%. All sessions will be supervised by trained professionals.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise detraining
Description: The exercise detraining will last 12 weeks without exercise.
Study: NCT02311192

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasonography B-scan
Description: The patient's eye will be anesthetized. The ultrasound probe will then be used to obtain images by keeping the probe in light contact with the eye.
Study: NCT00792129

Intervention type: DEVICE
Intervention: The Atavi System
Description: The primary device in the Atavi system is the Flex Posture retractor and accessories such as dilators and an Expander Instrument.~The Atavi System includes instruments used to access the spine by dilation of the overlying tissues, as well as a retracting device that is used to maintain the access. Once the retractor is in place, the visualization components of the system may be used.

Intervention type: DEVICE
Intervention: The Atavi System
Description: The primary device in the Atavi system is the Flex Posture retractor and accessories such as dilators and an Expander Instrument.~The Atavi System includes instruments used to access the spine by dilation of the overlying tissues, as well as a retracting device that is used to maintain the access. Once the retractor is in place, the visualization components of the system may be used.
Study: NCT02889510

Intervention type: DRUG
Group type: OTHER
Intervention: placebo
Description: 7-week subcutaneous placebo once daily
Study: NCT03229889

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cialis 5Mg Tablet
Description: Cialis is a PDE-5 inhibitor that has been shown to relax smooth muscle. Patients will be asked to 1 pill for 7 days prior to surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flomax 0.4Mg Capsule
Description: Tamsulosin is an alpha-blocker that has been shown to relax smooth muscle in the genitourinary system. Patients will be asked to 1 pill for 7 days prior to surgery.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Cialis + Flomax
Description: Cialis is a PDE-5 inhibitor that has been shown to relax smooth muscle. Tamsulosin is an alpha-blocker that has been shown to relax smooth muscle in the genitourinary system. A combination of these two drugs may increase the relaxation effects in the ureter. Patients will be asked to 1 of each pill for 7 days prior to surgery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This is plant cell based pill that contains no active ingredient. Patients will be asked to 1 pill for 7 days prior to surgery.
Study: NCT04567771

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Complete quality of life questionnaires
Study: NCT02476630

Intervention type: DEVICE
Intervention: StO2 measurement
Description: All participants will have a measurement of the tissue oxygen concentration (StO2) level after applying the noninvasive probe to the thenar eminence. This measurement is done at the same time as a blood gas from the central venous catheter is obtained. The StO2 measurement is documented once for the subject in the study.

Intervention type: OTHER
Intervention: Blood Gases
Description: All participants will have a measurement of the tissue oxygen concentration (StO2) level after applying the noninvasive probe to the thenar eminence. This measurement is done at the same time as a blood gas from the central venous catheter is obtained. The StO2 measurement is documented once for the subject in the study.
Study: NCT00558324

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LASIK
Description: Mechanical microkeratome Hansatome 160 microns

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LASIK
Description: Mechanical microkeratome K 3000 130 microns

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LASIK
Description: Femtoseconds laser 100 microns
Study: NCT00961493

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance based behavioral therapy
Description: 16 individual psychotherapy sessions focused on psychoeducation about anxiety, anxious responding, the function of emotions, mindfulness, and problems with efforts to constrict one's emotional experience; training in mindfulness skills; practice applying mindfulness skills in daily life, including acceptance of, rather than efforts to control, internal experience; and identification of values in areas of life and practice engaging in chosen actions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Applied relaxation
Description: 16 sessions of individual psychotherapy focused on psychoeducation about anxiety and anxious responding; training in multiple forms of relaxation; early cue detection; and practice applying relaxation in daily life.
Study: NCT02865434

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tc99m-tilmanocept
Description: Tilmanocept is a radiotracer that accumulates in macrophages by binding to a mannose binding receptor that resides on the surface.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tc99m-tilmanocept
Description: Tilmanocept is a radiotracer that accumulates in macrophages by binding to a mannose binding receptor that resides on the surface.
Study: NCT02946255

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment As Usual
Description: Treatment as usual (TAU) involves the typical discharge procedures for clients from Unit 2, Forensic and EPU wards at CAMH. It includes referral to outpatient psychiatric services and relevant community supports with the transition facilitated by inpatient social work staff.
Study: NCT02973906

Intervention type: OTHER
Group type: OTHER
Intervention: ADAPT Self Directed web
Description: In the self-directed web-only ADAPT condition, participants have access to the full ADAPT website (10 modules, online discussion forum

Intervention type: OTHER
Group type: OTHER
Intervention: ADAPT individualized web-facilitated
Description: This condition comprises access to the full ADAPT web program as described above, with augmentation of individual facilitator web support (i.e. the facilitator connects via Google Hangout). Facilitators meet with families at a mutually convenient time weekly (10-14 weeks, approximately 3 sessions per month).

Intervention type: OTHER
Group type: OTHER
Intervention: Group-based ADAPT
Description: Groups will meet weekly for 120 minutes, at a time convenient to participants (usually early evening). Groups cover core ADAPT/PMTO topics:
Study: NCT02386761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single Ascending Dose (SAD)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multiple Ascending Dose (MAD)
Study: NCT03291145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beta Blockers
Description: With and without Beta Blockers

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone
Description: Brisk Standing before and after seven days treatment with Spironolactone
Study: NCT03718039

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTX-011
Description: HTX-011 (bupivacaine/meloxicam), up to but not to exceed 60 mg/1.8 mg, via instillation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTX-011
Description: HTX-011 (bupivacaine/meloxicam), up to but not to exceed 60 mg/1.8 mg, via instillation.
Study: NCT02865434

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tc99m-tilmanocept
Description: Tilmanocept is a radiotracer that accumulates in macrophages by binding to a mannose binding receptor that resides on the surface.
Study: NCT03718039

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTX-011
Description: HTX-011 (bupivacaine/meloxicam), up to but not to exceed 60 mg/1.8 mg, via instillation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Luer Lock applicator
Description: Applicator for instillation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Luer Lock applicator
Description: Applicator for instillation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Luer Lock applicator
Description: Applicator for instillation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vial access device
Description: Device for withdrawal of drug product.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vial access device
Description: Device for withdrawal of drug product.
Study: NCT04567771

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Complete adverse event assessments

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo proton or intensity modulated radiation therapy
Study: NCT03301415

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valganciclovir
Description: Valganciclovir, 16 mg/kg/dose given orally twice daily for four months
Study: NCT02393469

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pulmonary rehabilitation
Description: Exercises breathing exercises are performed on a cycle ergometer for 30 minutes, monitored by 50% of your maximum heart frequency, strengthening exercises for major muscle groups of the upper and lower limbs with charges based on 70% of one repetition maximum, muscle stretching test, and in expiratory pattern
Study: NCT02865434

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tc99m-tilmanocept
Description: Tilmanocept is a radiotracer that accumulates in macrophages by binding to a mannose binding receptor that resides on the surface.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tc99m-tilmanocept
Description: Tilmanocept is a radiotracer that accumulates in macrophages by binding to a mannose binding receptor that resides on the surface.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tc99m-tilmanocept
Description: Tilmanocept is a radiotracer that accumulates in macrophages by binding to a mannose binding receptor that resides on the surface.
Study: NCT02393469

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Education and self-management for COPD
Description: Two months of continuous and self management for COPD where patients know their disease, pathophysiology, treatment, exacerbation of symptoms, and better ways pharmacological treatment education will be conducted through a system of multidisciplinary lessons with professional Physiotherapists, Psychologists, Dieticians, Pharmacists , Physical Education Professionals and Doctors
Study: NCT03247673

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT-P16
Description: CT-P16 is a biosimilar product for Avastin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EU-approved Avastin
Description: EU-approved Avastin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: US-licensed Avastin
Description: US-licensed Avastin
Study: NCT02554838

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical activity
Description: Participants receive a weekly individual session of physical activity during 8 consecutive weeks conducted by a licensed physical therapist and focusing on muscle strengthening, flexibility, gait and balance retraining.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: Participants receive a weekly individual session of physical activity during 8 consecutive weeks conducted by a licensed physical therapist and focusing on muscle strengthening, flexibility, gait and balance retraining.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home assessment and modification
Description: Two home-based sessions of modification of the home environment by a licensed rehabilitation therapist, in order to increase the aera of mobility, the frequency of moving in this aera and the independence to move.
Study: NCT02865434

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Whole body planar SPECT imaging (18-20 Hours post-injection)
Description: Subjects enrolled in Groups 10-11 will receive a whole body planar SPECT scan performed 18-20 Hours post-injection for dosimetry.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood Collection for PK Testing (15 Mins Before Injection)
Description: Blood will be collected for subjects enrolled in Groups 10-11 for the purpose of PK analysis within 15 minutes prior to administration of Tc 99m tilmanocept
Study: NCT02554838

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home assessment and modification
Description: Two home-based sessions of modification of the home environment by a licensed rehabilitation therapist, in order to increase the aera of mobility, the frequency of moving in this aera and the independence to move.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy
Description: Participants receive during 8 consecutive weeks a weekly individual sessions of CBT and a booster session one month later conducted by a psychologist specialized in CBT focusing on : functional analysis, education about treatment and anxiety, relaxation training and progressive exposure in imagination then in vivo.
Study: NCT03269786

Intervention type: DIAGNOSTIC_TEST
Intervention: Liver function tests (ALT,AST,ALBUMIN,BILIRUBIN,INR,PC,CBC)
Description: Liver function tests will be assessed after endoscopic varisceal treatment for 6 monthes

Intervention type: DEVICE
Intervention: biannual ultrasonography
Description: portal vein diameter , portal vein velocity and flow direction, volume flow in portal vein , congetive index, spleen size.will be assessed after endoscopic varisceal treatment by using biannual ultrasonography for 6 monthes
Study: NCT02865434

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood Collection for PK Testing (15 Mins Before Injection)
Description: Blood will be collected for subjects enrolled in Groups 10-11 for the purpose of PK analysis within 15 minutes prior to administration of Tc 99m tilmanocept

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood Collection for PK Testing (after injection)
Description: Blood will be collected for subjects enrolled in Groups 10-11 for the purpose of PK analysis immediately following administration of Tc 99m tilmanocept (00:00)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood Collection for PK Testing (after injection)
Description: Blood will be collected for subjects enrolled in Groups 10-11 for the purpose of PK analysis immediately following administration of Tc 99m tilmanocept (00:00)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood Collection for PK Testing (15 minutes post injection)
Description: Blood will be collected for subjects enrolled in Groups 10-11 for the purpose of PK analysis at 15 ± 5 minutes post injection of Tc 99m tilmanocept

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood Collection for PK Testing (15 minutes post injection)
Description: Blood will be collected for subjects enrolled in Groups 10-11 for the purpose of PK analysis at 15 ± 5 minutes post injection of Tc 99m tilmanocept

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood Collection for PK Testing (60 minutes post injection)
Description: Blood will be collected for subjects enrolled in Groups 10-11 for the purpose of PK analysis at 60 ± 15 minutes post injection of Tc 99m tilmanocept

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood Collection for PK Testing (60 minutes post injection)
Description: Blood will be collected for subjects enrolled in Groups 10-11 for the purpose of PK analysis at 60 ± 15 minutes post injection of Tc 99m tilmanocept

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood Collection for PK Testing (180 minutes post injection)
Description: Blood will be collected for subjects enrolled in Groups 10-11 for the purpose of PK analysis at 180 ± 15 minutes post injection of Tc 99m tilmanocept

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood Collection for PK Testing (180 minutes post injection)
Description: Blood will be collected for subjects enrolled in Groups 10-11 for the purpose of PK analysis at 180 ± 15 minutes post injection of Tc 99m tilmanocept
Study: NCT02113280

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arthroscopy
Description: Patients to receive knee arthroscopy and meniscal debridement

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy
Description: Outpatient standardised physiotherapy regime with focus on exercise therapy
Study: NCT04098783

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home visit, health education
Study: NCT02865434

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood Collection for PK Testing (18-20 hours post injection)
Description: Blood will be collected for subjects enrolled in Groups 10-11 for the purpose of PK analysis at 18-20 hours post injection of Tc 99m tilmanocept

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood Collection for PK Testing (18-20 hours post injection)
Description: Blood will be collected for subjects enrolled in Groups 10-11 for the purpose of PK analysis at 18-20 hours post injection of Tc 99m tilmanocept

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Planar Image with both Hands in Field of View
Description: Subjects in Groups 1-9 and Groups 10 and 11 will receive planar imaging with both hands in the field of view at 60 and 180 minutes post-injection.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Planar Image with both Hands in Field of View
Description: Subjects in Groups 1-9 and Groups 10 and 11 will receive planar imaging with both hands in the field of view at 60 and 180 minutes post-injection.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Planar Image with both Hands in Field of View
Description: Subjects in Groups 1-9 and Groups 10 and 11 will receive planar imaging with both hands in the field of view at 60 and 180 minutes post-injection.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Planar Image with both Hands in Field of View
Description: Subjects in Groups 1-9 and Groups 10 and 11 will receive planar imaging with both hands in the field of view at 60 and 180 minutes post-injection.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Planar Image with both Hands in Field of View
Description: Subjects in Groups 1-9 and Groups 10 and 11 will receive planar imaging with both hands in the field of view at 60 and 180 minutes post-injection.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Planar Image with both Hands in Field of View
Description: Subjects in Groups 1-9 and Groups 10 and 11 will receive planar imaging with both hands in the field of view at 60 and 180 minutes post-injection.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Planar Image with both Hands in Field of View
Description: Subjects in Groups 1-9 and Groups 10 and 11 will receive planar imaging with both hands in the field of view at 60 and 180 minutes post-injection.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Planar Image with both Hands in Field of View
Description: Subjects in Groups 1-9 and Groups 10 and 11 will receive planar imaging with both hands in the field of view at 60 and 180 minutes post-injection.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Planar Image with both Hands in Field of View
Description: Subjects in Groups 1-9 and Groups 10 and 11 will receive planar imaging with both hands in the field of view at 60 and 180 minutes post-injection.